As U.S. public health officials try to determine whether Zika has arrived in the country, doctors are establishing guidelines on how to care for the rising number of babies whose mothers were infected with the virus during pregnancy.
Gilead Sciences Inc. announced that two Phase 3b switch studies evaluating Odefsey (emtricitabine 200mg/rilpivirine 25mg/tenofovir alafenamide 25mg) for the treatment of HIV-1 infection met their primary objectives.
Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab
Merck said the U.S. Food and Drug Administration has requested the submission of new data and analyses from the MODIFY I and MODIFY II clinical trials previously submitted to the pending Biologics Licensing Application for bezlotoxumab, an investigational agent for prevention of Clostridium difficile (C. difficile) infection recurrence.
Healthcare agencies were brought together for the Medical Advertising Hall of Fame’s “View from the Top” leadership forum.
Britain’s decision to leave the European Union threatens to undermine its position as a center for drug research and UK patients could fall behind others in Europe in getting access to new drugs, Roche’s chief executive said.
Amgen Inc. and Allergan Plc said their copycat version of Roche Holding AG’s blockbuster cancer treatment, Herceptin, was found as effective as the original in a late-stage study.
Biogen reported Q2 profit that blew past Wall Street estimates; Chief Executive George Scangos will step down in the coming months once a successor is found.
Blood-testing company Theranos Inc. said it hired two executives to oversee regulatory, quality and compliance standards, as the company tries to recover from a series of regulatory sanctions and investigations.
Aegerion Pharmaceuticals continues to struggle as it moves to merge with QLT Inc. Aegerion has announced that not only will it withdraw its high cholesterol drug lomitapide from the European Union and other global markets, the company will also slash another 13 percent of its workforce.
Roche beat market expectations for adjusted net income in the first-half 2016, helped by cancer drug sales but also inflated by a one-off gain from its pensions scheme.
Galenica has agreed to buy Relypsa for $1.53 billion, paying a big premium for the Californian biotech company to strengthen its Vifor Pharma unit ahead of splitting up the Swiss healthcare group.
Swiss biotechnology firm Actelion raised its guidance for a second time, buoyed by strong uptake of its new pulmonary arterial hypertension (PAH) medicines.
Amgen announced that it has entered into an agreement with plaintiffs to resolve In re Amgen Inc. Securities Litigation, CV-07-2536 PSG, a previously disclosed securities class action lawsuit pending in the United States District Court for the Central District of California.
Promotions demonstrate agency commitment to strategic thinking and client-focused delivery excellence July 20, 2016, PHILADELPHIA, Penn. — Razorfish Health, a uniquely integrated health marketing agency, announces the promotion of three individuals on the Account Management team. Lisa Turzio has been promoted to SVP, Group Account Director, Sarah Bast to VP, Group Account Director and […]
Being sedentary, at least in moderation, is unlikely to cause heart disease, according to a new review of past research.
Abbott Laboratories reported better-than-expected quarterly sales and profit with strong sales in its medical device business.
EU antitrust regulators said they had cleared generic drugmaker Mylan’s planned cash-and-stock purchase of Sweden’s Meda subject to it selling certain assets.
Makers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly.
Drugmaking giant Merck is setting up a new West Coast headquarters in the Bay Area.
After a lengthy clinical hold by the U.S. Food and Drug Administration, Boston-based Zafgen has decided to halt development of obesity drug beloranib, shift its focus to another obesity drug (ZGN-1061) and lay off 34 percent of its staff. In addition, two executives are leaving the company.